Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

KM, Gillooly; C, Pulicicchio; MA, Pattoli; L, Cheng; S, Skala; EM, Heimrich; KW, McIntyre; TL, Taylor; DW, Kukral; S, Dudhgaonkar; J, Nagar; D, Banas; SH, Watterson; JA, Tino; A, Fura; JR, Burke

doi:10.1371/journal.pone.0181782

Public

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

Shared by NobleBlocks on Jul 24, 2017 • 12:00 AM UTC

Authors:

Gillooly KM

Pulicicchio C

Pattoli MA

Abstract

Bruton's tyrosine kinase (BTK) regulates critical signal transduction pathways involved in the pathobiology of rheumatoid arthritis (RA) and other autoimmune disorders. BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK currently being investigated in clinical tri...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!